Health Technologies

Psilocybin therapy helps clinicians process COVID depression, study finds

Psilocybin-assisted psychotherapy resulted in significant reductions in depression among US clinicians who provided front-line COVID-19 care in 2020 and 2021, results from a double-blind, randomised clinical trial have found.

These reductions were measurably greater than those experienced by the cohort of clinicians who received a placebo instead.

The findings provide evidence, lead investigator Dr Anthony Back said, that guided psilocybin therapy is “dramatically different” than conventional psychotherapy.

Back is an oncologist, palliative care specialist and professor at the University of Washington School of Medicine in Seattle.

He said: “For doctors and nurses who feel burned out or disillusioned or disconnected from the patient care they want to provide, this study shows that psilocybin therapy is safe and can help these clinicians work through those feelings and get better.”

The research team began recruiting in December 2021, well into the pandemic’s second wave.

At that point, more than 800,000 US deaths had been attributed to the SARS-CoV-2 virus.

About 2,200 clinicians from across the United States applied for the study’s 30 slots.

The participants — all clinicians who met criteria for providing front-line pandemic care — were chosen by lottery.

All had seen death and dying at a rate and intensity they had never experienced before, Back said.

At the study’s outset, the participants were confirmed as having no prepandemic mental health diagnoses but currently experiencing moderate to severe symptoms of depression, as measured by a rating scale.

They were then randomised to the psilocybin group or the control group, but without knowing which group.

Back said the 30 enrollees described being exhausted and experiencing crises of confidence, emotional detachment from patients, withdrawal from loved ones and colleagues, and, for some, doubts about whether their medical career was still viable.

The researcher said: “Some people who came into the study were really in despair.

“A number of people said, ‘I feel like a robot. I know I’m doing the right things technically.

“I know I’m saying the right words, but I say them and I’m talking to families who have a loved one who is dying, and I feel nothing — and I know that something is wrong.’”

The study compared whether two preparation sessions, followed by a single session using synthesized psilocybin (25 mg dose), followed by three integration sessions reduced participants’ depression symptoms more effectively than the same sequence of sessions with a placebo (niacin, 100 mg).

Two facilitators experienced in psychedelic-based counseling conducted the intervention sessions.

From participants’ first prep session to 28 days later, psilocybin group members’ depression symptoms declined by an average of 21.33 points, per the rating scale, compared with an average reduction of 9.33 for placebo group members.

Among the 15 people who got the placebo, depression scores dropped slightly, on average, but the people in the psilocybin group had “much larger drops that were quicker … and were more durable,” he said.

Back said: “I think psilocybin gave them the opportunity to really see their own feelings and see their own situation in a way that they could have more compassion for themselves and more understanding about what had really happened.

“It was effective because it gave them a new perspective on what they were facing, in a way that they could take action.”

After the participants had completed the day 28 questionnaire, thereby finalising the study data, the researchers invited those who had received the placebo to go through the same sequence of sessions with psilocybin.

Will Koenig, a critical-care flight nurse, said receiving counseling with a placebo resulted in “no change, no improvement, no decrease in burnout.”

His subsequent session with psilocybin, however, was “completely different.”

Koenig said: “It gave me this sense that (human) suffering can be transcended and transformed, and that’s our natural state.

“It seemed like I was creating the suffering I was experiencing … and that letting myself be tied up in in suffering that I created can only detract from the care that I provide to future patients.”

Avatar

admin

About Author

You may also like

Health Technologies

Accelerating Strategies Around Internet of Medical Things Devices

  • December 22, 2022
IoMT Device Integration with the Electronic Health Record Is Growing By their nature, IoMT devices are integrated into healthcare organizations’
Health Technologies

3 Health Tech Trends to Watch in 2023

Highmark Health also uses network access control technology to ensure computers are registered and allowed to join the network. The